Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HM-3
- Development stage
- Preclinical
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Intravitreal
01
Overview
HM-3 is an RGD-modified endostatin-derived **polypeptide** functioning as a potent angiogenesis inhibitor. It primarily acts as an anti-angiogenesis therapy, targeting pathological neovascularization. HM-3 has been specifically investigated for the treatment of age-related macular degeneration and choroidal neovascularization. Mechanistically, it acts by inhibiting endothelial cell proliferation and new blood vessel formation, likely interfering with integrins binding to extracellular matrix components[1]. Its main route of administration described in preclinical and early studies is intraocular (intravitreal) injection. The developer responsible for initial synthesis and studies is not explicitly named, but literature identifies "our laboratory" (most likely a Chinese academic/biotechnology group as described in preclinical studies)[1].
- Other names
- HM-3HM3HM 3RGD-endostatin polypeptide
02
Targets
αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on HM-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HM-3.